Home Advanced Medicine Invitae Reports 47% Growth in Quarterly Revenue and Volume Year-Over-Year – Yahoo Finance

Invitae Reports 47% Growth in Quarterly Revenue and Volume Year-Over-Year – Yahoo Finance

56 min read
0
15


<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="— On track to deliver more than 500,000 test samples and more than $220 million in revenue in 2019 —” data-reactid=”11″>— On track to deliver more than 500,000 test samples and more than $220 million in revenue in 2019 —

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="— Signed eight new biopharma partnerships in the quarter, expanding the breadth of the genome network —” data-reactid=”12″>— Signed eight new biopharma partnerships in the quarter, expanding the breadth of the genome network —

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="— Management hosting conference call and webcast today at 4:30pm Eastern/1:30pm Pacific —” data-reactid=”13″>— Management hosting conference call and webcast today at 4:30pm Eastern/1:30pm Pacific —

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="SAN FRANCISCO, May 7, 2019 /PRNewswire/ –&nbsp;Invitae Corporation (NVTA), the leader in advanced medical genetics, today announced financial and operating results for the first quarter ended March 31, 2019.” data-reactid=”14″>SAN FRANCISCO, May 7, 2019 /PRNewswire/ — Invitae Corporation (NVTA), the leader in advanced medical genetics, today announced financial and operating results for the first quarter ended March 31, 2019.

Data supports the utility of genetic testing amongst broader patient populations
Data supports the utility of genetic testing amongst broader patient populations

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content=""We've seen another first quarter of foundational growth across all of our customer segments, with strong momentum putting us well on our way to exceed our 2019 guidance and in 2020 to serve more than one million patients with more than $500 million in revenue," said Sean George, co-founder and chief executive officer of Invitae. "Invitae is rapidly becoming the preferred provider of genetic information for clinicians and biopharma partners and increasingly the partner of choice for third party commercial payers seeking to improve patient outcomes and lower healthcare costs. We intend to continue driving the transformation of the genetics industry as we further extend our leadership position in bringing genetics into mainstream medicine, improving patient outcomes and lowering costs for everyone."” data-reactid=”35″>”We’ve seen another first quarter of foundational growth across all of our customer segments, with strong momentum putting us well on our way to exceed our 2019 guidance and in 2020 to serve more than one million patients with more than $500 million in revenue,” said Sean George, co-founder and chief executive officer of Invitae. “Invitae is rapidly becoming the preferred provider of genetic information for clinicians and biopharma partners and increasingly the partner of choice for third party commercial payers seeking to improve patient outcomes and lower healthcare costs. We intend to continue driving the transformation of the genetics industry as we further extend our leadership position in bringing genetics into mainstream medicine, improving patient outcomes and lowering costs for everyone.”

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="First Quarter 2019 Financial Results” data-reactid=”36″>First Quarter 2019 Financial Results

  • Accessioned more than 94,000 samples in the first quarter of 2019, representing a 47% increase over the more than 64,000 samples in the first quarter of 2018. Billable volume was approximately 87,000 in the first quarter of 2019
  • Generated revenue of $40.6 million in the first quarter of 2019, representing a 47% increase over the first quarter of 2018 revenue of $27.7 million
  • Reduced the average cost per sample to $226 in the first quarter of 2019, representing a 19% reduction from a $279 average cost per sample in the first quarter of 2018
  • Achieved gross profit of $19.3 million in the first quarter of 2019 which is double the $9.6 million gross profit in the first quarter of 2018

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="Total operating expenses, which exclude cost of revenue, for the first quarter of 2019 were $55.5 million compared to $46.1 million in the first quarter of 2018. For the first quarter of 2019, Invitae reported a net loss of $37.7 million, or a $0.47 loss per share, compared to a net loss of $36.1 million in the first quarter of 2018, or a $0.66 net loss per share.” data-reactid=”42″>Total operating expenses, which exclude cost of revenue, for the first quarter of 2019 were $55.5 million compared to $46.1 million in the first quarter of 2018. For the first quarter of 2019, Invitae reported a net loss of $37.7 million, or a $0.47 loss per share, compared to a net loss of $36.1 million in the first quarter of 2018, or a $0.66 net loss per share.

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="In the first quarter of 2019, Invitae completed a public offering of common stock, resulting in gross proceeds of $196.7 million and net proceeds of $184.5 million.” data-reactid=”43″>In the first quarter of 2019, Invitae completed a public offering of common stock, resulting in gross proceeds of $196.7 million and net proceeds of $184.5 million.

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="As of March 31, 2019, cash, cash equivalents, restricted cash, and marketable securities totaled $287.1 million. Net increase in cash, cash equivalents and restricted cash for the quarter was $140.2 million, with cash burn for the quarter at $29.6 million.&nbsp;&nbsp;” data-reactid=”44″>As of March 31, 2019, cash, cash equivalents, restricted cash, and marketable securities totaled $287.1 million. Net increase in cash, cash equivalents and restricted cash for the quarter was $140.2 million, with cash burn for the quarter at $29.6 million.  

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content=""We are committed to making the investments necessary to meet our 2020 goals," said Shelly Guyer, chief financial officer of Invitae. "To that end, we have capital totaling nearly $300 million, which we will invest in advancing the development of our total cancer care offering, accelerating the development and commercialization of our new direct channel for patients, and continuing to invest in further engineering capabilities to reduce costs, add content and enhance the quality of our offering overall."” data-reactid=”45″>”We are committed to making the investments necessary to meet our 2020 goals,” said Shelly Guyer, chief financial officer of Invitae. “To that end, we have capital totaling nearly $300 million, which we will invest in advancing the development of our total cancer care offering, accelerating the development and commercialization of our new direct channel for patients, and continuing to invest in further engineering capabilities to reduce costs, add content and enhance the quality of our offering overall.”

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="Invitae’s Corporate and Scientific Highlights” data-reactid=”46″>Invitae’s Corporate and Scientific Highlights

  • Announced the availability of non-invasive prenatal screening (NIPS) using maternal cell-free DNA, rounding out Invitae’s comprehensive women’s health genetic testing services
  • Named as one of seven labs in UnitedHealthcare’s (UHC) Preferred Lab Network designed to make it easier for providers to choose from UHC’s broader network of more than 300 labs, based on a rigorous quality review process
  • Presented various studies at The American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting generated by researchers from Invitae
  • Published data in the Journal of Clinical Oncology by Invitae scientists in collaboration with researchers from the TME Breast Care Network showing that current guidelines for genetic testing of breast cancer patients miss as many patients with pathogenic variants as they find. The American Society of Breast Surgeons (ASBS) revised its genetic testing guidelines for hereditary breast cancer to include all patients with a personal history of breast cancer
  • Collaborated with investigators at Tulane Cancer Center on the largest study to date on the genetics of prostate cancer. The study, published in JAMA Oncology, found that guidelines for genetic testing of prostate cancer patients excluded a substantial number of patients with disease causing genetic variants from having genetic testing done and concluded that broader genetic testing of patients with prostate cancer is warranted
  • Extended Invitae’s genome network by signing eight new biopharma partnership contracts since the beginning of the year

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="Webcast and Conference Call Details
Management will host a conference call and webcast today at 4:30 p.m. Eastern / 1:30 p.m.&nbsp; Pacific to discuss financial results and recent developments. The dial-in numbers for the conference call are (866) 393-4306 for domestic callers and (734) 385-2616 for international callers, and the reservation number for both is 3435689. Following prepared remarks, management will respond to questions from investors and analysts, subject to time limitations.&nbsp;” data-reactid=”54″>Webcast and Conference Call Details
Management will host a conference call and webcast today at 4:30 p.m. Eastern / 1:30 p.m.  Pacific to discuss financial results and recent developments. The dial-in numbers for the conference call are (866) 393-4306 for domestic callers and (734) 385-2616 for international callers, and the reservation number for both is 3435689. Following prepared remarks, management will respond to questions from investors and analysts, subject to time limitations. 

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="The live webcast of the call may be accessed by visiting the investors section of the company's website at&nbsp;ir.invitae.com. A replay of the webcast will be available shortly after the conclusion of the call and will be archived on the company’s website.” data-reactid=”55″>The live webcast of the call may be accessed by visiting the investors section of the company’s website at ir.invitae.com. A replay of the webcast will be available shortly after the conclusion of the call and will be archived on the company’s website.

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="About Invitae
Invitae Corporation (NVTA)&nbsp;is the leading advanced medical genetics company, whose mission is to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people. Invitae’s goal is to aggregate the world’s genetic tests into a single service with higher quality, faster turnaround time, and lower prices. For more information, visit the company’s website at&nbsp;invitae.com.” data-reactid=”60″>About Invitae
Invitae Corporation (NVTA) is the leading advanced medical genetics company, whose mission is to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people. Invitae’s goal is to aggregate the world’s genetic tests into a single service with higher quality, faster turnaround time, and lower prices. For more information, visit the company’s website at invitae.com.

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the company’s financial results for the quarter ended March 31, 2019; estimated guidance for 2019 and future financial performance; the timing and impact of the company’s partnerships, product offerings and distribution channels; investment plans; and the company’s beliefs regarding the growth of its business, its position and impact on the genetic testing industry, its success in executing on its mission and achieving its goals, and the benefits of genetic testing. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the actual results for the quarter ended March 31, 2019; the company’s ability to continue to grow its business; the company’s history of losses; the company’s ability to compete; the company’s failure to manage growth effectively; the company’s need to scale its infrastructure in advance of demand for its tests and to increase demand for its tests; the risk that the company may not obtain or maintain sufficient levels of reimbursement for its tests; the company’s failure to successfully integrate or fully realize the anticipated benefits of acquired businesses; the company’s ability to use rapidly changing genetic data to interpret test results accurately and consistently; security breaches, loss of data and other disruptions; laws and regulations applicable to the company’s business; and the other risks set forth in the company’s Annual Report on Form 10-K for the year ended December 31, 2018. These forward-looking statements speak only as of the date hereof, and Invitae Corporation disclaims any obligation to update these forward-looking statements.” data-reactid=”61″>Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the company’s financial results for the quarter ended March 31, 2019; estimated guidance for 2019 and future financial performance; the timing and impact of the company’s partnerships, product offerings and distribution channels; investment plans; and the company’s beliefs regarding the growth of its business, its position and impact on the genetic testing industry, its success in executing on its mission and achieving its goals, and the benefits of genetic testing. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the actual results for the quarter ended March 31, 2019; the company’s ability to continue to grow its business; the company’s history of losses; the company’s ability to compete; the company’s failure to manage growth effectively; the company’s need to scale its infrastructure in advance of demand for its tests and to increase demand for its tests; the risk that the company may not obtain or maintain sufficient levels of reimbursement for its tests; the company’s failure to successfully integrate or fully realize the anticipated benefits of acquired businesses; the company’s ability to use rapidly changing genetic data to interpret test results accurately and consistently; security breaches, loss of data and other disruptions; laws and regulations applicable to the company’s business; and the other risks set forth in the company’s Annual Report on Form 10-K for the year ended December 31, 2018. These forward-looking statements speak only as of the date hereof, and Invitae Corporation disclaims any obligation to update these forward-looking statements.

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="Non-GAAP Financial Measures
To supplement Invitae’s consolidated financial statements prepared in accordance with generally accepted accounting principles in the United States (GAAP), the company monitors and considers cash burn, which is a non-GAAP financial measure. This non-GAAP financial measure is not based on any standardized methodology prescribed by GAAP and is not necessarily comparable to similarly-titled measures presented by other companies. Cash burn excludes (1) changes in marketable securities other than investments made in privately held companies, (2) cash received from equity financings, including proceeds from a public offering of common stock in March 2019, (3) cash received from loan proceeds, and (4) cash received from exercises of warrants. Management believes cash burn is a liquidity measure that provides useful information to management and investors about the amount of cash consumed by the operations of the business. A limitation of using this non-GAAP measure is that cash burn does not represent the total change in cash, cash equivalents, and restricted cash for the period because it excludes cash provided by or used for other operating, investing or financing activities. Management accounts for this limitation by providing information about its operating, investing and financing activities in the statements of cash flows in its consolidated financial statements in its most recent Quarterly Report on Form&nbsp;10-Q&nbsp;and Annual Report on Form&nbsp;10-K&nbsp;and by presenting net cash provided by (used in) operating, investing and financing activities as well as the net increase in cash, cash equivalents and restricted cash in its reconciliation of cash burn.&nbsp;In addition, other companies, including companies in the same industry, may not use cash burn, may calculate cash burn in a different manner than management or may use other financial measures to evaluate their performance, all of which could reduce the usefulness of cash burn as a comparative measure.” data-reactid=”62″>Non-GAAP Financial Measures
To supplement Invitae’s consolidated financial statements prepared in accordance with generally accepted accounting principles in the United States (GAAP), the company monitors and considers cash burn, which is a non-GAAP financial measure. This non-GAAP financial measure is not based on any standardized methodology prescribed by GAAP and is not necessarily comparable to similarly-titled measures presented by other companies. Cash burn excludes (1) changes in marketable securities other than investments made in privately held companies, (2) cash received from equity financings, including proceeds from a public offering of common stock in March 2019, (3) cash received from loan proceeds, and (4) cash received from exercises of warrants. Management believes cash burn is a liquidity measure that provides useful information to management and investors about the amount of cash consumed by the operations of the business. A limitation of using this non-GAAP measure is that cash burn does not represent the total change in cash, cash equivalents, and restricted cash for the period because it excludes cash provided by or used for other operating, investing or financing activities. Management accounts for this limitation by providing information about its operating, investing and financing activities in the statements of cash flows in its consolidated financial statements in its most recent Quarterly Report on Form 10-Q and Annual Report on Form 10-K and by presenting net cash provided by (used in) operating, investing and financing activities as well as the net increase in cash, cash equivalents and restricted cash in its reconciliation of cash burn. In addition, other companies, including companies in the same industry, may not use cash burn, may calculate cash burn in a different manner than management or may use other financial measures to evaluate their performance, all of which could reduce the usefulness of cash burn as a comparative measure.

Because of these limitations, cash burn should not be considered in isolation from, or as a substitute for, financial information prepared in accordance with GAAP. Investors are encouraged to review the reconciliation of net increase in cash, cash equivalents and restricted cash to cash burn provided in the table below.

INVITAE CORPORATION

Consolidated Balance Sheets

(in thousands)

(unaudited)

March 31,
2019

December 31,
2018

Assets

Current assets:

Cash and cash equivalents

$

252,502

$

112,158

Marketable securities

28,714

13,727

Accounts receivable

23,700

26,296

Prepaid expenses and other current assets

16,569

13,258

Total current assets

321,485

165,439

Property and equipment, net

25,757

27,886

Operating lease assets

37,290

Restricted cash

5,871

6,006

Intangible assets, net

29,156

30,469

Goodwill

50,095

50,095

Other assets

6,845

3,064

Total assets

$

476,499

$

282,959

Liabilities and stockholders’ equity

Current liabilities:

Accounts payable

$

9,867

$

7,812

Accrued liabilities

25,354

26,563

Operating lease obligations

4,419

Finance lease obligations

1,960

1,937

Total current liabilities

41,600

36,312

Operating lease obligations, net of current portion

42,634

Finance lease obligations, net of current portion

875

1,375

Debt

74,828

74,477

Other long-term liabilities

150

8,956

Total liabilities

160,087

121,120

Stockholders’ equity:

Common stock

9

8

Accumulated other comprehensive income (loss)

8

(5)

Additional paid-in capital

870,784

678,548

Accumulated deficit

(554,389)

(516,712)

Total stockholders’ equity

316,412

161,839

Total liabilities and stockholders’ equity

$

476,499

$

282,959

 

INVITAE CORPORATION

Consolidated Statements of Operations

(in thousands, except per share data)

(unaudited)

Three Months Ended
March 31,

2019

2018

Revenue:

Test revenue

$

39,619

$

27,053

Other revenue

934

618

Total revenue

40,553

27,671

Cost of revenue

21,254

18,076

Research and development

17,994

15,366

Selling and marketing

24,193

18,924

General and administrative

13,319

11,780

Loss from operations

(36,207)

(36,475)

Other income, net

638

1,647

Interest expense

(2,108)

(1,292)

Net loss

$

(37,677)

$

(36,120)

Net loss per share, basic and diluted

$

(0.47)

$

(0.66)

Shares used in computing net loss per share, basic and diluted

79,369

54,382

 

INVITAE CORPORATION

Consolidated Statements of Cash Flows

(in thousands)

(unaudited)

Three Months Ended March 31,

2019

2018

Cash flows from operating activities:

Net loss

$

(37,677)

$

(36,120)

Adjustments to reconcile net loss to net cash used in operating activities:

Depreciation and amortization

3,286

3,433

Stock-based compensation

5,223

4,393

Remeasurements of liabilities associated with business combinations

(130)

1,093

Other

388

32

Changes in operating assets and liabilities:

Accounts receivable

2,596

(224)

Prepaid expenses and other current assets

(3,365)

(1,156)

Other assets

1,019

(2,548)

Accounts payable

(307)

(1,574)

Accrued expenses and other liabilities

601

(231)

Net cash used in operating activities

(28,366)

(32,902)

Cash flows from investing activities:

Purchases of marketable securities

(20,781)

(225)

Proceeds from sales of marketable securities

19,965

Proceeds from maturities of marketable securities

6,000

2,078

Purchases of property and equipment

(2,764)

(1,871)

Net cash provided by (used in) in investing activities

(17,545)

19,947

Cash flows from financing activities:

Proceeds from public offerings of common stock, net of issuance costs

184,490

Proceeds from issuance of common stock

2,107

191

Proceeds from debt financing

19,792

Finance lease principal payments

(477)

(638)

Net cash provided by financing activities

186,120

19,345

Net increase in cash, cash equivalents and restricted cash

140,209

6,390

Cash, cash equivalents and restricted cash at beginning of period

118,164

17,459

Cash, cash equivalents and restricted cash at end of period

$

258,373

$

23,849

 

INVITAE CORPORATION

Reconciliation of Net Increase in Cash, Cash Equivalents and Restricted Cash to Cash Burn

(in thousands)

(unaudited)

Three Months Ended March 31,

2019

2018

Net cash used in operating activities

(28,366)

(32,902)

Net cash provided by (used in) investing activities

(17,545)

19,947

Net cash provided by financing activities

186,120

19,345

Net increase in cash, cash equivalents and restricted cash

140,209

6,390

Adjustments:

Purchases of investments

20,781

225

Sales of investments

(19,965)

Maturities of investments

(6,000)

(2,078)

Purchases of investments in privately held companies

(225)

Proceeds from public offering of common stock, net of issuance costs

(184,490)

Net proceeds from issuance of debt

(19,792)

Proceeds from exercises of warrants

(88)

(191)

Cash burn

(29,588)

(35,636)

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="Contact:
Laura D’Angelo
ir@invitae.com
(628) 213-3369″ data-reactid=”75″>Contact:
Laura D’Angelo
ir@invitae.com
(628) 213-3369

Invitae's (NVTA) mission is to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. www.invitae.com (PRNewsFoto/Invitae Corporation)Invitae's (NVTA) mission is to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. www.invitae.com (PRNewsFoto/Invitae Corporation)
Invitae’s (NVTA) mission is to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. www.invitae.com (PRNewsFoto/Invitae Corporation)
Cision

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="View original content to download multimedia:http://www.prnewswire.com/news-releases/invitae-reports-47-growth-in-quarterly-revenue-and-volume-year-over-year-300845599.html” data-reactid=”107″>View original content to download multimedia:http://www.prnewswire.com/news-releases/invitae-reports-47-growth-in-quarterly-revenue-and-volume-year-over-year-300845599.html

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="span.prnews_spanfont-size:8pt !important;font-family:"Arial" !important;color:black !important; a.prnews_acolor:blue !important; li.prnews_lifont-size:8pt !important;font-family:"Arial" !important;color:black !important; p.prnews_pfont-size:0.62em !important;font-family:"Arial" !important;color:black !important;margin:0in !important; .prngen22BORDER-TOP:1pt !important; BORDER-RIGHT:1pt !important; VERTICAL-ALIGN: BOTTOM !important; BORDER-BOTTOM:1pt !important; TEXT-ALIGN: LEFT !important; PADDING-LEFT:1.17em !important; BORDER-LEFT:1pt !important; PADDING-RIGHT:0.50em !important; .prngen3BORDER-TOP:1pt !important; BORDER-RIGHT:1pt !important; VERTICAL-ALIGN: BOTTOM !important; BORDER-BOTTOM:1pt !important; TEXT-ALIGN: CENTER !important; PADDING-LEFT:0.50em !important; BORDER-LEFT:1pt !important; PADDING-RIGHT:0.67em !important; .prngen14BORDER-TOP:1pt !important; BORDER-RIGHT:1pt !important; VERTICAL-ALIGN: BOTTOM !important; BORDER-BOTTOM:black 1pt solid !important; TEXT-ALIGN: RIGHT !important; PADDING-LEFT:0.50em !important; BORDER-LEFT:1pt !important; PADDING-RIGHT:0.50em !important; .prngen17BORDER-TOP:1pt !important; BORDER-RIGHT:1pt !important; VERTICAL-ALIGN: BOTTOM !important; BORDER-BOTTOM:1pt !important; PADDING-LEFT:1.17em !important; BORDER-LEFT:1pt !important; PADDING-RIGHT:0.50em !important; .prngen18BORDER-TOP:black 1pt solid !important; BORDER-RIGHT:1pt !important; VERTICAL-ALIGN: BOTTOM !important; BORDER-BOTTOM:black 2pt double !important; TEXT-ALIGN: RIGHT !important; PADDING-LEFT:0.50em !important; BORDER-LEFT:1pt !important; PADDING-RIGHT:0.50em !important; .prngen8BORDER-TOP:1pt !important; BORDER-RIGHT:1pt !important; VERTICAL-ALIGN: BOTTOM !important; BORDER-BOTTOM:black 1pt solid !important; TEXT-ALIGN: RIGHT !important; PADDING-LEFT:0.50em !important; BORDER-LEFT:1pt !important; PADDING-RIGHT:0.67em !important; .prngen9BORDER-TOP:1pt !important; BORDER-RIGHT:1pt !important; VERTICAL-ALIGN: BOTTOM !important; BORDER-BOTTOM:1pt !important; PADDING-LEFT:1.67em !important; BORDER-LEFT:1pt !important; PADDING-RIGHT:0.50em !important; .prngen16BORDER-TOP:black 1pt solid !important; BORDER-RIGHT:1pt !important; VERTICAL-ALIGN: BOTTOM !important; BORDER-BOTTOM:1pt !important; TEXT-ALIGN: CENTER !important; PADDING-LEFT:0.50em !important; BORDER-LEFT:1pt !important; PADDING-RIGHT:0.67em !important; .prngen19BORDER-TOP:1pt !important; BORDER-RIGHT:1pt !important; VERTICAL-ALIGN: BOTTOM !important; BORDER-BOTTOM:black 2pt double !important; TEXT-ALIGN: RIGHT !important; PADDING-LEFT:0.50em !important; BORDER-LEFT:1pt !important; PADDING-RIGHT:0.50em !important; .prngen13BORDER-TOP:1pt !important; BORDER-RIGHT:1pt !important; VERTICAL-ALIGN: BOTTOM !important; BORDER-BOTTOM:1pt !important; TEXT-ALIGN: RIGHT !important; PADDING-LEFT:0.50em !important; BORDER-LEFT:1pt !important; PADDING-RIGHT:0.50em !important; .prngen11BORDER-TOP:black 1pt solid !important; BORDER-RIGHT:1pt !important; VERTICAL-ALIGN: BOTTOM !important; BORDER-BOTTOM:black 2pt double !important; TEXT-ALIGN: RIGHT !important; PADDING-LEFT:0.50em !important; BORDER-LEFT:1pt !important; PADDING-RIGHT:0.67em !important; .prngen15BORDER-TOP:black 1pt solid !important; BORDER-RIGHT:1pt !important; VERTICAL-ALIGN: BOTTOM !important; BORDER-BOTTOM:black 1pt solid !important; TEXT-ALIGN: CENTER !important; PADDING-LEFT:0.50em !important; BORDER-LEFT:1pt !important; PADDING-RIGHT:0.67em !important; .prngen10BORDER-TOP:1pt !important; BORDER-RIGHT:1pt !important; VERTICAL-ALIGN: BOTTOM !important; BORDER-BOTTOM:black 2pt double !important; TEXT-ALIGN: RIGHT !important; PADDING-LEFT:0.50em !important; BORDER-LEFT:1pt !important; PADDING-RIGHT:0.67em !important; .prngen12BORDER-TOP:black 1pt solid !important; BORDER-RIGHT:1pt !important; VERTICAL-ALIGN: BOTTOM !important; BORDER-BOTTOM:1pt !important; TEXT-ALIGN: RIGHT !important; PADDING-LEFT:0.50em !important; BORDER-LEFT:1pt !important; PADDING-RIGHT:0.67em !important; .prngen20BORDER-TOP:1pt !important; BORDER-RIGHT:1pt !important; VERTICAL-ALIGN: BOTTOM !important; BORDER-BOTTOM:1pt !important; TEXT-ALIGN: LEFT !important; PADDING-LEFT:0.50em !important; BORDER-LEFT:1pt !important; PADDING-RIGHT:0.67em !important; .prngen4BORDER-TOP:1pt !important; BORDER-RIGHT:1pt !important; VERTICAL-ALIGN: BOTTOM !important; BORDER-BOTTOM:black 1pt solid !important; TEXT-ALIGN: CENTER !important; PADDING-LEFT:0.50em !important; BORDER-LEFT:1pt !important; PADDING-RIGHT:0.50em !important; .prngen2BORDER-TOP:1pt !important; BORDER-RIGHT:1pt !important; VERTICAL-ALIGN: BOTTOM !important; BORDER-BOTTOM:1pt !important; TEXT-ALIGN: CENTER !important; PADDING-LEFT:0.50em !important; BORDER-LEFT:1pt !important; PADDING-RIGHT:0.50em !important; .prngen6BORDER-TOP:1pt !important; BORDER-RIGHT:1pt !important; VERTICAL-ALIGN: BOTTOM !important; BORDER-BOTTOM:1pt !important; TEXT-ALIGN: RIGHT !important; PADDING-LEFT:0.50em !important; BORDER-LEFT:1pt !important; PADDING-RIGHT:0.67em !important; .prngen25BORDER-TOP:black 1pt solid !important; BORDER-RIGHT:1pt !important; VERTICAL-ALIGN: BOTTOM !important; BORDER-BOTTOM:black 1pt solid !important; TEXT-ALIGN: RIGHT !important; PADDING-LEFT:0.50em !important; BORDER-LEFT:1pt !important; PADDING-RIGHT:0.67em !important; .prngen7BORDER-TOP:1pt !important; BORDER-RIGHT:1pt !important; VERTICAL-ALIGN: BOTTOM !important; BORDER-BOTTOM:1pt !important; PADDING-LEFT:0.84em !important; BORDER-LEFT:1pt !important; PADDING-RIGHT:0.50em !important; .prngen23BORDER-TOP:1pt !important; BORDER-RIGHT:1pt !important; VERTICAL-ALIGN: BOTTOM !important; BORDER-BOTTOM:1pt !important; TEXT-ALIGN: LEFT !important; PADDING-LEFT:1.67em !important; BORDER-LEFT:1pt !important; PADDING-RIGHT:0.50em !important; .prngen21BORDER-TOP:1pt !important; BORDER-RIGHT:1pt !important; VERTICAL-ALIGN: BOTTOM !important; BORDER-BOTTOM:1pt !important; TEXT-ALIGN: LEFT !important; PADDING-LEFT:0.50em !important; BORDER-LEFT:1pt !important; PADDING-RIGHT:0.50em !important; .prngen5BORDER-TOP:1pt !important; BORDER-RIGHT:1pt !important; VERTICAL-ALIGN: BOTTOM !important; BORDER-BOTTOM:1pt !important; PADDING-LEFT:0.50em !important; BORDER-LEFT:1pt !important; PADDING-RIGHT:0.50em !important; .prntblnsBORDER-TOP: 1pt !important; BORDER-RIGHT: 1pt !important; BORDER-COLLAPSE: collapse !important; BORDER-BOTTOM: 1pt !important; BORDER-LEFT: 1pt !important; .prnsbr1BORDER-RIGHT:1pt !important; .prnvabVERTICAL-ALIGN: BOTTOM !important; .prntarTEXT-ALIGN: RIGHT !important; .prnpr6PADDING-RIGHT:0.50em !important; .prnpl6PADDING-LEFT:0.50em !important; .prnsbtsBORDER-TOP:black 1pt solid !important; .prnsbbsBORDER-BOTTOM:black 1pt solid !important; .prnsbl1BORDER-LEFT:1pt !important; ;} ” data-reactid=”108″>span.prnews_spanfont-size:8pt !important;font-family:”Arial” !important;color:black !important; a.prnews_acolor:blue !important; li.prnews_lifont-size:8pt !important;font-family:”Arial” !important;color:black !important; p.prnews_pfont-size:0.62em !important;font-family:”Arial” !important;color:black !important;margin:0in !important; .prngen22BORDER-TOP:1pt !important; BORDER-RIGHT:1pt !important; VERTICAL-ALIGN: BOTTOM !important; BORDER-BOTTOM:1pt !important; TEXT-ALIGN: LEFT !important; PADDING-LEFT:1.17em !important; BORDER-LEFT:1pt !important; PADDING-RIGHT:0.50em !important; .prngen3BORDER-TOP:1pt !important; BORDER-RIGHT:1pt !important; VERTICAL-ALIGN: BOTTOM !important; BORDER-BOTTOM:1pt !important; TEXT-ALIGN: CENTER !important; PADDING-LEFT:0.50em !important; BORDER-LEFT:1pt !important; PADDING-RIGHT:0.67em !important; .prngen14BORDER-TOP:1pt !important; BORDER-RIGHT:1pt !important; VERTICAL-ALIGN: BOTTOM !important; BORDER-BOTTOM:black 1pt solid !important; TEXT-ALIGN: RIGHT !important; PADDING-LEFT:0.50em !important; BORDER-LEFT:1pt !important; PADDING-RIGHT:0.50em !important; .prngen17BORDER-TOP:1pt !important; BORDER-RIGHT:1pt !important; VERTICAL-ALIGN: BOTTOM !important; BORDER-BOTTOM:1pt !important; PADDING-LEFT:1.17em !important; BORDER-LEFT:1pt !important; PADDING-RIGHT:0.50em !important; .prngen18BORDER-TOP:black 1pt solid !important; BORDER-RIGHT:1pt !important; VERTICAL-ALIGN: BOTTOM !important; BORDER-BOTTOM:black 2pt double !important; TEXT-ALIGN: RIGHT !important; PADDING-LEFT:0.50em !important; BORDER-LEFT:1pt !important; PADDING-RIGHT:0.50em !important; .prngen8BORDER-TOP:1pt !important; BORDER-RIGHT:1pt !important; VERTICAL-ALIGN: BOTTOM !important; BORDER-BOTTOM:black 1pt solid !important; TEXT-ALIGN: RIGHT !important; PADDING-LEFT:0.50em !important; BORDER-LEFT:1pt !important; PADDING-RIGHT:0.67em !important; .prngen9BORDER-TOP:1pt !important; BORDER-RIGHT:1pt !important; VERTICAL-ALIGN: BOTTOM !important; BORDER-BOTTOM:1pt !important; PADDING-LEFT:1.67em !important; BORDER-LEFT:1pt !important; PADDING-RIGHT:0.50em !important; .prngen16BORDER-TOP:black 1pt solid !important; BORDER-RIGHT:1pt !important; VERTICAL-ALIGN: BOTTOM !important; BORDER-BOTTOM:1pt !important; TEXT-ALIGN: CENTER !important; PADDING-LEFT:0.50em !important; BORDER-LEFT:1pt !important; PADDING-RIGHT:0.67em !important; .prngen19BORDER-TOP:1pt !important; BORDER-RIGHT:1pt !important; VERTICAL-ALIGN: BOTTOM !important; BORDER-BOTTOM:black 2pt double !important; TEXT-ALIGN: RIGHT !important; PADDING-LEFT:0.50em !important; BORDER-LEFT:1pt !important; PADDING-RIGHT:0.50em !important; .prngen13BORDER-TOP:1pt !important; BORDER-RIGHT:1pt !important; VERTICAL-ALIGN: BOTTOM !important; BORDER-BOTTOM:1pt !important; TEXT-ALIGN: RIGHT !important; PADDING-LEFT:0.50em !important; BORDER-LEFT:1pt !important; PADDING-RIGHT:0.50em !important; .prngen11BORDER-TOP:black 1pt solid !important; BORDER-RIGHT:1pt !important; VERTICAL-ALIGN: BOTTOM !important; BORDER-BOTTOM:black 2pt double !important; TEXT-ALIGN: RIGHT !important; PADDING-LEFT:0.50em !important; BORDER-LEFT:1pt !important; PADDING-RIGHT:0.67em !important; .prngen15BORDER-TOP:black 1pt solid !important; BORDER-RIGHT:1pt !important; VERTICAL-ALIGN: BOTTOM !important; BORDER-BOTTOM:black 1pt solid !important; TEXT-ALIGN: CENTER !important; PADDING-LEFT:0.50em !important; BORDER-LEFT:1pt !important; PADDING-RIGHT:0.67em !important; .prngen10BORDER-TOP:1pt !important; BORDER-RIGHT:1pt !important; VERTICAL-ALIGN: BOTTOM !important; BORDER-BOTTOM:black 2pt double !important; TEXT-ALIGN: RIGHT !important; PADDING-LEFT:0.50em !important; BORDER-LEFT:1pt !important; PADDING-RIGHT:0.67em !important; .prngen12BORDER-TOP:black 1pt solid !important; BORDER-RIGHT:1pt !important; VERTICAL-ALIGN: BOTTOM !important; BORDER-BOTTOM:1pt !important; TEXT-ALIGN: RIGHT !important; PADDING-LEFT:0.50em !important; BORDER-LEFT:1pt !important; PADDING-RIGHT:0.67em !important; .prngen20BORDER-TOP:1pt !important; BORDER-RIGHT:1pt !important; VERTICAL-ALIGN: BOTTOM !important; BORDER-BOTTOM:1pt !important; TEXT-ALIGN: LEFT !important; PADDING-LEFT:0.50em !important; BORDER-LEFT:1pt !important; PADDING-RIGHT:0.67em !important; .prngen4BORDER-TOP:1pt !important; BORDER-RIGHT:1pt !important; VERTICAL-ALIGN: BOTTOM !important; BORDER-BOTTOM:black 1pt solid !important; TEXT-ALIGN: CENTER !important; PADDING-LEFT:0.50em !important; BORDER-LEFT:1pt !important; PADDING-RIGHT:0.50em !important; .prngen2BORDER-TOP:1pt !important; BORDER-RIGHT:1pt !important; VERTICAL-ALIGN: BOTTOM !important; BORDER-BOTTOM:1pt !important; TEXT-ALIGN: CENTER !important; PADDING-LEFT:0.50em !important; BORDER-LEFT:1pt !important; PADDING-RIGHT:0.50em !important; .prngen6BORDER-TOP:1pt !important; BORDER-RIGHT:1pt !important; VERTICAL-ALIGN: BOTTOM !important; BORDER-BOTTOM:1pt !important; TEXT-ALIGN: RIGHT !important; PADDING-LEFT:0.50em !important; BORDER-LEFT:1pt !important; PADDING-RIGHT:0.67em !important; .prngen25BORDER-TOP:black 1pt solid !important; BORDER-RIGHT:1pt !important; VERTICAL-ALIGN: BOTTOM !important; BORDER-BOTTOM:black 1pt solid !important; TEXT-ALIGN: RIGHT !important; PADDING-LEFT:0.50em !important; BORDER-LEFT:1pt !important; PADDING-RIGHT:0.67em !important; .prngen7BORDER-TOP:1pt !important; BORDER-RIGHT:1pt !important; VERTICAL-ALIGN: BOTTOM !important; BORDER-BOTTOM:1pt !important; PADDING-LEFT:0.84em !important; BORDER-LEFT:1pt !important; PADDING-RIGHT:0.50em !important; .prngen23BORDER-TOP:1pt !important; BORDER-RIGHT:1pt !important; VERTICAL-ALIGN: BOTTOM !important; BORDER-BOTTOM:1pt !important; TEXT-ALIGN: LEFT !important; PADDING-LEFT:1.67em !important; BORDER-LEFT:1pt !important; PADDING-RIGHT:0.50em !important; .prngen21BORDER-TOP:1pt !important; BORDER-RIGHT:1pt !important; VERTICAL-ALIGN: BOTTOM !important; BORDER-BOTTOM:1pt !important; TEXT-ALIGN: LEFT !important; PADDING-LEFT:0.50em !important; BORDER-LEFT:1pt !important; PADDING-RIGHT:0.50em !important; .prngen5BORDER-TOP:1pt !important; BORDER-RIGHT:1pt !important; VERTICAL-ALIGN: BOTTOM !important; BORDER-BOTTOM:1pt !important; PADDING-LEFT:0.50em !important; BORDER-LEFT:1pt !important; PADDING-RIGHT:0.50em !important; .prntblnsBORDER-TOP: 1pt !important; BORDER-RIGHT: 1pt !important; BORDER-COLLAPSE: collapse !important; BORDER-BOTTOM: 1pt !important; BORDER-LEFT: 1pt !important; .prnsbr1BORDER-RIGHT:1pt !important; .prnvabVERTICAL-ALIGN: BOTTOM !important; .prntarTEXT-ALIGN: RIGHT !important; .prnpr6PADDING-RIGHT:0.50em !important; .prnpl6PADDING-LEFT:0.50em !important; .prnsbtsBORDER-TOP:black 1pt solid !important; .prnsbbsBORDER-BOTTOM:black 1pt solid !important; .prnsbl1BORDER-LEFT:1pt !important; ;}

Let’s block ads! (Why?)


Source link

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Check Also

SERBISYONG TOTOO NI MAYOR VICO SOTTO | HOW TO GET E-HEALTH CARD IN PASIG CITY

Universal Health Care, Ang kalusugan na Para sa lahat at abot kaya ng bawat isang mamamaya…